AWA
RXRX icon

Arkadios Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arkadios Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$50.6K – 1510
2025
Q2 		$50.6K Buy
+10,000
New +$49.1K ﹤0.01% 1286

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arkadios Wealth Advisors's RXRX Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 67% in Q2 2026, selling an estimated $78.4K and leaving 11,650 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Arkadios Wealth Advisors first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $222K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Arkadios Wealth Advisors held 11,650 shares of Recursion Pharmaceuticals worth $42.8K as of Q2 2026.
  • Arkadios Wealth Advisors sold 23,556 Recursion Pharmaceuticals shares in Q2 2026, an estimated $78.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #1725 holding.
  • Arkadios Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Arkadios Wealth Advisors's Recursion Pharmaceuticals position peaked at $222K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.